Amgen

AMGN Maintains Rating by Scotiabank -- Price Target Raised to $5

Scotiabank maintains Sector Outperform rating on Amgen, $500 price target

Scotiabank has maintained its Sector Outperform rating for Amgen with a $500 price target, suggesting a 19.6% upside from its previous close. This positive outlook is attributed to Amgen's strong product portfolio, strategic acquisitions like Horizon and Onyx Pharmaceuticals, and a commitment to innovation reflected in expected high-single-digit year-over-year growth in non-GAAP R&D expenditures.

Amgen stock last at USD 410.86, up 1.19 percent in New York trading

Amgen's stock closed at USD 410.86 in New York trading, marking a 1.19 percent increase. This rise surpassed the S&P 500's gain, despite elevated long-term Treasury yields and ongoing market uncertainties. The company's stock demonstrated resilience with an intraday range from USD 404.19 to USD 411.00.

Kailera Therapeutics (Nasdaq:KLRA) - Stock Analysis

Kailera Therapeutics (KLRA) is a clinical-stage biopharmaceutical company focused on developing therapies for obesity and related conditions. The company recently reported positive Phase 3 data for its oral GLP-1 receptor agonist KAI-7535, showing significant weight loss and HbA1c reductions. KLRA is preparing for global Phase 3 trials for its Ribupatide candidates and has appointed a new CTO, indicating late-stage development and commercialization efforts, despite current unprofitability and a short cash runway.

Amgen Inc Stock (AMGN) Moved Up by 3.90% on Sep 22: Facts Behind the Movement

Amgen Inc. (AMGN) stock rose by 3.90% on September 22, driven by positive Phase 3 clinical trial results for dazodalibep in Sjögren's disease, which met its primary endpoint. The company's diverse late-stage pipeline, including its obesity candidate MariTide and oncology treatment IMDELLTRA, also contributed to investor confidence. Despite technical indicators showing a neutral to sell signal, analysts maintain an average price target of $389.14 with a "Hold" rating.

David J. Taylor Purchases Amgen and Home Depot Stocks, Sells Marathon Petroleum

Congressman David J. Taylor has recently adjusted his investment portfolio by purchasing shares in Amgen Inc. and Home Depot, Inc., while selling shares in Marathon Petroleum Corporation. All transactions, valued between $1,001 and $15,000 each, were executed on September 22, 2026, and reported on October 1, 2026. Amgen, a biopharmaceutical company, is noted for its strong returns and undervalued status according to InvestingPro analysis, having raised its dividend for 15 consecutive years.

Merck shares may rise as key clinical trial results in oncology and other areas approach.

Bank of America maintains a 'buy' rating on Merck, anticipating a potential share re-rating due to upcoming clinical trial data in oncology and other pipeline areas. Key trials include Phase 3 results for SAC-TMT in lung cancer and data on intismeran, a personalized cancer vaccine developed with Moderna, with presentations expected at the European Society for Medical Oncology meeting. Despite a recent dip, Merck maintains a strong market cap and positive investor interest.